Evotec SE(US:EVO)2020-11-12 16:35Financial Performance (9M 2020) - Group revenues increased by 12% to €360.4 million compared to €321.4 million in 9M 2019 [11] - Like-for-like growth of the base business, adjusted for portfolio and FX effects, was up by 19% [11] - Adjusted Group EBITDA was €76.9 million, compared to €93.2 million in 9M 2019, but showed a strong upswing in Q3 [11] - Increased investment in unpartnered R&D expenses to €33.4 million, up from €25.7 million in 9M 2019 [11] - R&D expenses reached €46.1 million, a 12% increase from €41.3 million in 9M 2019 [17] Q3 2020 Highlights - Revenue growth was driven by strong performance in the base business, with improved revenues from milestones, upfronts, and licenses [21] - Revenues from contracts with customers reached €129.4 million in Q3 2020, compared to €114.3 million in Q3 2019 [21] Guidance 2020 - Total Group revenues are expected to range from €440 million to €480 million, based on constant 2019 exchange rates [11, 48] - Adjusted Group EBITDA is expected to be in the range of €100 million to €120 million [11, 48] - Unpartnered Group R&D expenses are projected to be approximately €45 million [11, 48] Strategic Investments and Partnerships - Mubadala Investment Company made a €200 million investment, translating into 5.6% of the total new number of 163.5 million Evotec shares [15]